Summary
The global Tumor Necrosis Factor Receptor Superfamily Member 18 Market is expected to witness a CAGR of xx% over the forecast period 2020-2026 and is expected to reach US$ xx million in 2026, from US$ xx million in 2019.
TNFSF18, also known as the tumor necrosis factor receptor superfamily member 18, is a type II transmembrane protein expressed on DC, monocytes, macrophages, activated T cells, endothelial cells, osteoclasts, and a variety of other cell types. It is also present in various types of tumors. Molecular and cellular studies suggest that TNFRSF18 plays an important role in regulating T-cell receptor-mediated cell death. The human TNFSF18 recombinant was purified using conventional chromatography methods. TNFRSF18 is one of four members of the TNF superfamily. Members of this family are also known as CD357, LAG-3, and CD127. When activated by TNF, they can induce the death of certain cancer cells. However, tumor cells are unable to produce TNF by themselves. It is important to note that tumor cells do not express TNFRSF18 in healthy tissues.
Drivers:
The global tumor necrosis factor receptor superfamily member 18 market is projected to expand at a faster rate than the overall market due to factors such as high adoption in various therapeutic trials as a pivotal modulator to increase T cell proliferation and survival. For instance, In October 2021, researchers at the National Cancer Institute in Bethesda, Maryland reported that TNFRSF9 (tumor necrosis factor receptor superfamily member 9) in combination with PTN (pleiotrophin) protein can effectively predict cancer-related mortality in African American patients with 78.2% accuracy.
Furthermore, the growing acceptance across the healthcare sector to reduce inflammation in patients suffering from autoimmune bowel diseases is expected to boost the growth of the global tumor necrosis factor receptor superfamily member 18 market during the forecast period.
Restraints:
Stringent approval pathways for biosimilars and poor understanding of this mechanism are expected to limit the growth of the global tumor necrosis factor receptor superfamily member 18 market.
Regional Insights:
On the basis of geography, the North American area is in the driver's seat for the global tumor necrosis factor receptor superfamily member 18 market, owing to the high expenditure on the biotechnology sector and increasing cases of inflammatory bowel disease.
Another important geographic area driving the global tumor necrosis factor receptor superfamily member 18 market is Asia Pacific, which is benefiting from the increasing prominence of clinically-approved TNF drugs and their growing application in developing cancer immunotherapies.
Competitive Landscape:
- Major companies contributing to the global tumor necrosis factor receptor superfamily member 18 market include Incyte Corp., Five Prime Therapeutics, Inc., Apogenix GmbH, Novartis AG, Ablynx NV, Regeneron Pharmaceuticals, Inc., Amgen Inc., OncoMed Pharmaceuticals Inc., Bristol-Myers Squibb Company, Merck & Co Inc., and MedImmune LLC.
- In June 2021, a research team at Nanjing University of Chinese Medicine revealed the results of their clinical trial, concluding that the active component, icariin, showed a positive therapeutic effect in patients suffering from ischemic stroke, glioblastoma, and depression disorder.
The Tumor Necrosis Factor Receptor Superfamily Member 18 Market report highlights product development and growth strategies such as merger and acquisition adopted by market players along with SWOT Analysis, PEST and Porter’s Five Forces analyses of the Tumor Necrosis Factor Receptor Superfamily Member 18 Market, which highlight the strengths, weaknesses, opportunities, and commination of key companies. Moreover, the report offers two distinct market forecasts, one from the perspective of the producer and another from that of the consumer.
The various contributors involved in the value chain of the product include manufacturers, suppliers, distributors, intermediaries, and customers.
The Key Manufacturers covered in this Report:-
- Ablynx NV
- Amgen Inc
- Apogenix GmbH
- Bristol-Myers Squibb Company
- Five Prime Therapeutics Inc
- Incyte Corp
- MedImmune LLC
- Merck & Co Inc
- Novartis AG
- OncoMed Pharmaceuticals Inc
- Regeneron Pharmaceuticals Inc
By the Product Type, the market is primarily segmented into:
- AMG-228
- BMS-986156
- FPA-154
- GWN-323
- INCAGN-1876
- Others
By Applications, the market is segmented into:
- Melanoma
- Non-Small Cell Lung Cancer
- Gastric Cancer
- Blood Cancer
- Others
The report covers the following Regions:
- North America
- United States
- Canada
- Mexico
- Asia Pacific
- China
- Japan
- South Korea
- India
- Australia
- Indonesia
- Thailand
- Malaysia
- Philippines
- Vietnam
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Central & South America
- Middle East & Africa
- Turkey
- GCC Countries
- Egypt
- South Africa
Objective of the Tumor Necrosis Factor Receptor Superfamily Member 18 Market Report:
- To assess the size of the market by value and volume
- Analyze the Tumor Necrosis Factor Receptor Superfamily Member 18 Market in terms of regions and major countries
- Highlight recent developments and trends in the market
- Offer perceptive data regarding major market players in terms of key developments, strategies, and product portfolio
- Determine share of the Tumor Necrosis Factor Receptor Superfamily Member 18 Market in terms of various segments such as by product type, application, and end-user
- Offer accurate projection of the market for the forecast period using state–of–the–art tools and the current primary and secondary research approaches
- Discuss major factors that impact growth of the Tumor Necrosis Factor Receptor Superfamily Member 18 Market
The Tumor Necrosis Factor Receptor Superfamily Member 18 Market engages the readers with all pivotal approaches to understand their position in the industry based on revenue or sales growth. The report efficiently evaluates the Tumor Necrosis Factor Receptor Superfamily Member 18 Market from various dimensions to deliver an end-product that is informative, elaborate, and accurate and includes detailed market segmentation, regional analysis, and competition in the market. The information in the report is backed by annual company reports, financial reports, press releases, regulatory databases, government documents, and statistical databases.
For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Key Stakeholders:
- Material suppliers/wholesalers
- Market Distributors/traders
- Regulatory bodies
- Research organizations, and consulting firms
- Commercial research & developments (R&D)
- Trade associations and industry bodies
- Importers and exporters
- End-use industries
Available Customizations:
Custom research is one of the most crucial components of the business strategy that helps an organization gain insight into specific business sector, aligned with its specific area of interest. Thus, SMI offers more accurate, pragmatic, and actionable information specifically tailored to suit your business needs.
Request Discount 
Inquire Before Buy
